Terms: = Lymphoma AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1
1434 results:
1. Sintilimab (anti-pd-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract] [Full Text] [Related]
2. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H; von Itzstein MS; Fattah F; Liu J; Zhu C; Xie Y; Wakeland EK; Park JY; Kahl BS; Diefenbach CS; Gerber DE
Oncoimmunology; 2024; 13(1):2351255. PubMed ID: 38737792
[TBL] [Abstract] [Full Text] [Related]
3. Paradigm Shifts in Hodgkin lymphoma Treatment: From Frontline Therapies to Relapsed Disease.
Burton C; Allen P; Herrera AF
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433502. PubMed ID: 38728605
[TBL] [Abstract] [Full Text] [Related]
4. Systematic analysis of mucosal-associated invariant T cells in haematological malignancies.
Bacova B; Cierny J; Nemcekova L; Smetanova/Brozova J; Novak J
Scand J Immunol; 2024 Jun; 99(6):e13364. PubMed ID: 38720521
[TBL] [Abstract] [Full Text] [Related]
5. Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma.
Lee WWL; Lim JQ; Tang TPL; Tan D; Koh SM; Puan KJ; Wang LW; Lim J; Tan KP; Chng WJ; Lim ST; Ong CK; Rotzschke O
Front Immunol; 2024; 15():1346178. PubMed ID: 38680487
[TBL] [Abstract] [Full Text] [Related]
6. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
[TBL] [Abstract] [Full Text] [Related]
7. Combination of chidamide and pd-1 blockade in Refractory/Relapsed aggressive large B-cell lymphomas with high risk of failing CAR-T therapy.
Wang Z; Xu H; Mei Y; Xiao M; Cao Y; Huang L; Yang Z; Zhang Y; Han Z; Zheng M; Hong Z
Int Immunopharmacol; 2024 May; 133():112014. PubMed ID: 38615378
[TBL] [Abstract] [Full Text] [Related]
8. Expression and prognostic significance of the pd-1/PD-L1 pathway in AIDS-related non-Hodgkin lymphoma.
Zhao H; Cai S; Xiao Y; Xia M; Chen H; Xie Z; Tang X; He H; Peng J; Chen J
Cancer Med; 2024 Apr; 13(7):e7195. PubMed ID: 38613207
[TBL] [Abstract] [Full Text] [Related]
9. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
Wang T; Zhang L; Cheng Y
Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
[TBL] [Abstract] [Full Text] [Related]
10. Correlation Between ImageJ and Conventional Manual Scoring Methods for Programmed Death-Ligand 1 Immuno-Histochemically Stained Sections.
Al Taher RS; Abbas MA; Halahleh K; Sughayer MA
Technol Cancer Res Treat; 2024; 23():15330338241242635. PubMed ID: 38562094
[No Abstract] [Full Text] [Related]
11. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.
Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ
Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract] [Full Text] [Related]
13. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell lymphoma.
Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
[TBL] [Abstract] [Full Text] [Related]
14. [Progress in treatment of primary mediastinal large B-cell lymphoma].
Chen LW; Li JY; Fan L
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):98-102. PubMed ID: 38527847
[TBL] [Abstract] [Full Text] [Related]
15. Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report.
Giannotti F; De Ramon Ortiz C; Simonetta F; Morin S; Bernardi C; Masouridi-Levrat S; Chalandon Y; Mamez AC
Front Immunol; 2024; 15():1360275. PubMed ID: 38510239
[TBL] [Abstract] [Full Text] [Related]
16. Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.
Han L; Xing H; Cao W; Song Y; Jiang Z; Yu J
Expert Opin Biol Ther; 2024 Apr; 24(4):221-223. PubMed ID: 38506624
[TBL] [Abstract] [Full Text] [Related]
17. Differential Upregulation of Th1/Th17-Associated Proteins and PD-L1 in Granulomatous Mycosis Fungoides.
Marques-Piubelli ML; Navarrete J; Ledesma DA; Hudgens CW; Lazcano RN; Alani A; Huen A; Duvic M; Nagarajan P; Aung PP; Wistuba II; Curry JL; Miranda RN; Torres-Cabala CA
Cells; 2024 Feb; 13(5):. PubMed ID: 38474383
[TBL] [Abstract] [Full Text] [Related]
18. Anti-metabolic agent pegaspargase plus pd-1 antibody sintilimab for first-line treatment in advanced natural killer T cell lymphoma.
Xiong J; Cheng S; Gao X; Yu SH; Dai YT; Huang XY; Zhong HJ; Wang CF; Yi HM; Zhang H; Cao WG; Li R; Tang W; Zhao Y; Xu PP; Wang L; Zhao WL
Signal Transduct Target Ther; 2024 Mar; 9(1):62. PubMed ID: 38448403
[TBL] [Abstract] [Full Text] [Related]
19. Correlation between pd-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics.
Wang L; Cao C; Qiu J; Zhang J; He Q; Song L; Xie L; Ma J
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):44-50. PubMed ID: 38430041
[TBL] [Abstract] [Full Text] [Related]
20. Clinical and Real-World Effectiveness of Mogamulizumab: A Narrative Review.
Fernández-Guarino M; Ortiz P; Gallardo F; Llamas-Velasco M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396877
[TBL] [Abstract] [Full Text] [Related]
[Next]